Trial record 1 of 1 for:    IC83 and Pemetrexed
Previous Study | Return to List | Next Study

Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00415636
First received: December 21, 2006
Last updated: August 30, 2010
Last verified: August 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)